Metabolism & weight
AOD-9604
hGH fragment 176–191 (modified)
A growth-hormone fragment developed for obesity that did not beat placebo in a larger trial.
What it is
A modified fragment from the end of human growth hormone. It was developed in Australia in the 1990s and 2000s as an anti-obesity drug.
How it's thought to work
It was designed to copy growth hormone's fat-breakdown effect without its effects on growth or blood sugar.
What the evidence shows
Early studies looked promising. A larger phase 2b trial in roughly 500 people with obesity found no meaningful weight loss compared with placebo, and development as an obesity drug was stopped.
Regulatory status
Not approved as a medicine anywhere. Prohibited in sport by the World Anti-Doping Agency (WADA).
Safety notes
It was generally well tolerated in trials, but injectable products sold online are unregulated.
Key sources
- Metabolic Pharmaceuticals. Phase 2b obesity trial results (company announcement), 2007.
Educational summary only, not medical advice. Gtides does not sell or link to sellers of AOD-9604 or any other product. Products sold as “research peptides” are not approved medicines, and their contents, purity and sterility are not verified.